A Phase 1, First-in-Human, multicenter, open-label trial of DS9051b in participants with advanced or metastatic adrenocortical carcinoma (ACC) and metastatic castration resistant prostate cancer (mCRPC)
Phase 1 trial of DS9051b in patients with prostate cancer and adrenocortical carcinoma
Sponsor: Daiichi Sankyo
Enrolling: Male and Female Patients
IRB Number: AAAV9907
U.S. Govt. ID: NCT07189403
Contact: Alexander Wei: / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this trial is to learn more about an investigational drug called DS9051b. DS9051b is an investigational drug that is not Food and Drug Administration (FDA) approved for your disease. This is a first in human study. It is being studied to see if it is safe, and if your disease improves while taking it.
Investigator
Alexander Wei, MD
Do You Qualify?
Do you have advanced prostate cancer or adrenocortical carcinoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Alexander Wei
cancerclinicaltrials@cumc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE